Source:http://linkedlifedata.com/resource/pubmed/id/10655276
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2000-2-24
|
| pubmed:abstractText |
It is widely agreed that hepatitis B virus immunoglobulin (HBIG) should be administered for at least 12 months to patients transplanted for hepatitis B virus (HBV)-related diseases to prevent HBV recurrence. No data are available, however, on how long this treatment should be used, and most centers currently administer HBIG on a life-long basis. Herein, we report the results of a new prophylactic strategy aiming at the discontinuation of HBIG treatment and consisting of the administration of double dose recombinant HBV vaccine (0, 1-, and 6-month schedule) to liver transplant recipients fulfilling the following criteria: (1) liver transplantation for conditions related to nonreplicative HBV infection (hepatitis B surface antigen [HBsAg] positive, hepatitis B e antigen [HBeAg] negative, and HBV DNA negative); (2) at least 18 months of HBIG administration; and (3) no HBV infection recurrence, normal or slightly altered liver graft function, and low-grade immunosuppression at the time of vaccination. Seventeen patients received HBV vaccination and 14 of them (82%) developed protective serum titers of anti-HBs (>10 IU/L). Six patients seroconverted after a first course of vaccination, whereas 8 patients required a second course (3 additional doses of vaccine). Responding patients were followed for a median of 14 months (range, 3-50) after seroconversion. During this period no HBV recurrence occurred and in only 2 patients a decrease of anti-HBs titers below 10 UI/L was observed. Our data suggest that in selected liver transplant recipients, posttransplantation HBV vaccination may be a useful and cost-effective strategy in the prophylaxis of HBV recurrence, allowing the discontinuation of life-long HBIG treatment.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
0270-9139
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
31
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
496-501
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:10655276-Adult,
pubmed-meshheading:10655276-Drug Administration Schedule,
pubmed-meshheading:10655276-Female,
pubmed-meshheading:10655276-Forecasting,
pubmed-meshheading:10655276-Hepatitis B,
pubmed-meshheading:10655276-Hepatitis B Antigens,
pubmed-meshheading:10655276-Humans,
pubmed-meshheading:10655276-Immunization, Passive,
pubmed-meshheading:10655276-Immunoglobulins,
pubmed-meshheading:10655276-Liver Diseases,
pubmed-meshheading:10655276-Liver Transplantation,
pubmed-meshheading:10655276-Male,
pubmed-meshheading:10655276-Middle Aged,
pubmed-meshheading:10655276-Postoperative Period,
pubmed-meshheading:10655276-Preventive Medicine,
pubmed-meshheading:10655276-Recurrence,
pubmed-meshheading:10655276-Treatment Outcome,
pubmed-meshheading:10655276-Vaccination
|
| pubmed:year |
2000
|
| pubmed:articleTitle |
Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation.
|
| pubmed:affiliation |
Institut Clinic de Malalties Digestives, Hospital Clínic Barcelona, University of Barcelona, Barcelona, Spain.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|